News
Moving towards composite biomarkers for disease management
Relevant and reliable biomarkers are the key to implementing personalised medicine in clinical practice. While single biomarkers have guided the treating physicians and researchers for decades, scientific developments over the past decades, suggest that it might be...
eNose technology, a promising diagnostic tool for ILD
Interstitial lung diseases (ILD) are a diverse group of over 200 different lung diseases that are classified together because of their similarities in e.g. clinical, radiological and pathological features [i]. Since the course of the disease, treatment choices and...
10 questions for Peter Sterk, Scientific Adviser
Peter Sterk has launched exhaled breath analysis by eNose in various clinical settings. Peter is a biomedical scientist (MD with a PhD in Physiology) trying to incorporate novel biological information into the diagnosis and management of patients with respiratory...
Exhaled breath analysis for prediction of response to Immunotherapy
The emergence of cancer immunotherapy has revolutionized the treatment paradigm for advanced cancers across a wide range of tumor types and has brought hope to thousands of patients suffering from malignancies. The underlying concept for the development of these...
10 questions for Michael Rutgers, Lung Foundation Netherlands
One of Michael Rutgers’ aims is to help prevent smoking in children and young people and help adults to quit smoking. Michael is the Managing Director of the Lung Foundation Netherlands, passionately committed to promoting clean-air and healthy lungs. How would you...
The importance and impact of real-world studies in breathomics
Currently, the SpiroNose, a cloud-connected electronic nose (eNose), is included in more than 30 clinical studies investigating the accuracy of exhaled breath analysis for e.g. (early) diagnosis and phenotyping of diseases ranging from respiratory diseases, different...
BreathBase: eNose technology linked to a powerful cloud solution
The innovative cloud solution, BreathBase, is developed by Breathomix in collaboration with technology partners Microsoft and Tecknoworks conform the (inter)national requirements of the following standards: ISO 27001 (Information Security) and NEN 7510 (Information...
Point-of-care precision medicine in patients with asthma
Asthma is a common chronic disease of the airways that affects people of all ages. The ‘chronic’ nature of the disease requires long-term and sometimes life-long treatments to help patients maintain an optimal quality of life. Unfortunately, there is still no cure for...
Is it possible to measure COVID-19 infection in exhaled breath?
This is the question that the Netherlands Research Institute for Public Health (RIVM) asked us amid the Covid-19 outbreak. To provide a clear answer, we have started a multi-centre prospective clinical study in patients and healthcare personnel with a suspected...
Why exhaled breath analysis is an appealing option
Personalized medicine requires capturing complex and dynamic biological information of each individual patient. Despite the significant advances in the field, these technologies require extensive laboratory procedures and thereby, they cannot be easily applied in...
The development of the cloud-connected eNose: SpiroNose
The scientific development of the 'SpiroNose', a technically and clinically validated electronic nose specifically designed for use in the doctor's office, is the result of the combined efforts of the multidisciplinary team of researchers from the Amsterdam University...
Early detection of lung cancer in COPD using the SpiroNose
Last week our Scientific Project Manager, Niloufar Farzan, attended the Breath Summit conference (IABR) in Leicestershire, UK to meet and listen to world-renowned researchers in breath research. The Breath Summit conference is held annually and provides great...